Nabsys demise shouldn’t end investing

Last week Nabsys Inc. shut its doors, costing approximately 40 people their jobs and investors about $50 million. That’s the nature of the beast in the high-risk biotech field. But by some of the reaction to the company’s failure, it is clear that the loss is not going down easily. The reason is that the

Already a Subscriber? Log in

To Continue Reading This Article

Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.

Learn More and Become a Subscriber

No posts to display